Publications by authors named "S Coutre"
Article Synopsis
- The treatment options for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have improved, especially with the introduction of targeted therapies like BTK and BCL-2 inhibitors.
- These therapies offer a chemotherapy-free alternative for patients who are newly diagnosed or have relapsed/refractory disease.
- Research indicates that having undetectable minimal residual disease post-treatment is a key indicator of better survival rates, prompting updates to the NCCN Guidelines on treatment recommendations.
Background: Few therapies are approved for hospitalized patients with severe coronavirus disease 2019 (COVID-19). Ibrutinib, a once-daily Bruton tyrosine kinase inhibitor, may mitigate COVID-19-induced lung damage by reducing inflammatory cytokines. The multicenter, randomized, double-blind phase 2 iNSPIRE study evaluated ibrutinib for prevention of respiratory failure in hospitalized patients with severe COVID-19.
View Article and Find Full Text PDFHerein, we present the long-term follow-up of the randomized E1912 trial comparing the long-term efficacy of ibrutinib-rituximab (IR) therapy to fludarabine, cyclophosphamide, and rituximab (FCR) and describe the tolerability of continuous ibrutinib. The E1912 trial enrolled 529 treatment-naïve patients aged ≤70 years with chronic lymphocytic leukemia (CLL). Patients were randomly assigned (2:1 ratio) to receive IR or 6 cycles of FCR.
View Article and Find Full Text PDF